Gilead Sciences announced second quarter financial results and showed an increase of $1.7 billion for overall product sales and an increase of $1.6 billion in antiviral product sales since the second quarter of 2014, due in large part to the sales of Harvoni, according to a press release from Gilead.
According to the financial report, total product sales for the second quarter of 2015 were $8.1 billion, an increase of $1.7 billion from $6.4 billion in sales of the 2014 second quarter. The sales in the U.S. alone increased to $5.6 billion from $4.8 billion in the second quarter of 2014 and product sales in Europe increased from $1.3 billion to $2 billion.
Continue reading @ Healio
No comments:
Post a Comment